RAPGEF3 and heart failure: Although constant β-ARs activation may facilitate the development of heart failure, β-adrenergic signaling in heart failure exerts both cardiotoxic and cardioprotective effects through the PKA and Epac dual pathways (Kwak et al., 2008; Zhang et al., 2013; Wang Y. et al., 2015).